Literature DB >> 7884412

Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer.

B Fisher, E P Mamounas.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7884412     DOI： 10.1200/JCO.1995.13.3.537

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  18 in total

1.  Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy.

Authors:  Maiko Takahashi; Hiromitsu Jinno; Tetsu Hayashida; Michio Sakata; Keiko Asakura; Yuko Kitagawa
Journal:  World J Surg       Date:  2012-12       Impact factor: 3.352

2.  Past, present, and future challenges in breast cancer treatment.

Authors:  George W Sledge; Eleftherios P Mamounas; Gabriel N Hortobagyi; Harold J Burstein; Pamela J Goodwin; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

3.  Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. French Northern Oncology Group.

Authors:  A Adenis; L Vanlemmens; C Fournier; B Hecquet; J Bonneterre
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 4.  NSABP breast cancer clinical trials: recent results and future directions.

Authors:  Eleftherios P Mamounas
Journal:  Clin Med Res       Date:  2003-10

5.  Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.

Authors:  Ksenija Kanjer; Svetislav Tatić; Zora Nešković-Konstantinović; Zaki Abu Rabi; Dragica Nikolić-Vukosavljević
Journal:  Pathol Oncol Res       Date:  2013-03-24       Impact factor: 3.201

6.  Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).

Authors:  G G Kimmick; C Cirrincione; D B Duggan; K Bhalla; N Robert; D Berry; L Norton; S Lemke; I C Henderson; C Hudis; E Winer
Journal:  Breast Cancer Res Treat       Date:  2008-02-28       Impact factor: 4.872

7.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.

Authors:  Viviana Londero; Massimo Bazzocchi; Chiara Del Frate; Fabio Puglisi; Carla Di Loreto; Giuliana Francescutti; Chiara Zuiani
Journal:  Eur Radiol       Date:  2004-02-18       Impact factor: 5.315

8.  State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments.

Authors:  Arnd Honig; Lorenz Rieger; Marc Sutterlin; Diethelm Wallwiener; Johannes Dietl; Erich-Franz Solomayer
Journal:  Ger Med Sci       Date:  2005-09-13

9.  Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.

Authors:  S Amat; P Bougnoux; F Penault-Llorca; F Fétissof; H Curé; F Kwiatkowski; J-L Achard; G Body; J Dauplat; P Chollet
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

Review 10.  Preoperative chemotherapy for women with operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.